Compare BXC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXC | ADCT |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.3M | 484.4M |
| IPO Year | 2004 | 2020 |
| Metric | BXC | ADCT |
|---|---|---|
| Price | $77.79 | $3.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $88.67 | $7.60 |
| AVG Volume (30 Days) | 88.4K | ★ 656.4K |
| Earning Date | 02-18-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $2,948,840,000.00 | $75,209,000.00 |
| Revenue This Year | $0.63 | $12.48 |
| Revenue Next Year | $3.06 | $5.12 |
| P/E Ratio | $45.89 | ★ N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $52.71 | $1.05 |
| 52 Week High | $106.01 | $4.80 |
| Indicator | BXC | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.73 | 53.45 |
| Support Level | $66.38 | $3.88 |
| Resistance Level | $80.34 | $4.10 |
| Average True Range (ATR) | 3.16 | 0.27 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 85.44 | 67.20 |
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).